Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking - PubMed (original) (raw)
Clinical Trial
. 2005 Dec;20(12):2739-45.
doi: 10.1093/ndt/gfi128. Epub 2005 Sep 27.
Affiliations
- PMID: 16188897
- DOI: 10.1093/ndt/gfi128
Clinical Trial
Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking
Charlotte Jones-Burton et al. Nephrol Dial Transplant. 2005 Dec.
Abstract
Background: Of the known risk factors for chronic kidney disease (CKD), race represents one that is non-modifiable, while smoking is another that is modifiable. Moreover, smoking tends to increase red blood cell mass, which is frequently diminished in CKD. No studies have examined the interplay of race with smoking on anaemia management in patients with CKD.
Methods: We examined the effects of smoking on anaemia management in CKD and its variation across race in a previously conducted study of CKD patients (n = 1312) initiated on weekly epoetin alfa and followed for 16 weeks. Smoking status was classified as current vs non-smoker. Race was classified as African-American vs non-African-American. Changes in estimated glomerular filtration rate, urinary albumin excretion, and erythropoietic response to weekly epoetin alfa were examined.
Results: Overall, African-Americans had lower baseline Hb than non-African-Americans. African-American non-smokers did not mount an erythropoetic response comparable to other non-smokers by final Hb (mean 11.29 g/dl vs 11.64 g/dl, P<0.001) or week 16 Hb (mean 11.61 g/dl vs 11.86 g/dl, P = 0.02). However, African-American smokers had a more significant erythropoietic response than their non-smoking counterparts and were comparable to their smoking non-African-American counterparts. There was no effect of smoking on renal function or urinary protein excretion over the course of the study.
Conclusion: African-American non-smokers exhibit a diminished response to standard epoetin alfa dosing than non-smokers in other races. However, African-American smokers with CKD exhibit a response to epoetin alfa comparable to patients of other races. These findings may have implications for African-Americans who have CKD-related anaemia.
Similar articles
- Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R, Bhaduri S, Singh AK; PROMPT Study Group. Provenzano R, et al. Clin Nephrol. 2005 Aug;64(2):113-23. doi: 10.5414/cnp64113. Clin Nephrol. 2005. PMID: 16114787 Clinical Trial. - Prevalence and treatment of anemia with once-weekly epoetin alfa in patients with diabetes and chronic kidney disease.
Lorber DL, Provenzano R, McClellan W. Lorber DL, et al. Endocr Pract. 2006 Sep-Oct;12(5):506-13. doi: 10.4158/EP.12.5.506. Endocr Pract. 2006. PMID: 17002925 Clinical Trial. - An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M, Thimons DG, Winston JL, Langholff W, McGowan T. Patel M, et al. J Am Med Dir Assoc. 2012 Mar;13(3):244-8. doi: 10.1016/j.jamda.2010.09.009. Epub 2010 Nov 11. J Am Med Dir Assoc. 2012. PMID: 21450214 Clinical Trial. - Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.
Hudson JQ, Sameri RM. Hudson JQ, et al. Pharmacotherapy. 2002 Sep;22(9 Pt 2):141S-149S. doi: 10.1592/phco.22.14.141s.33397. Pharmacotherapy. 2002. PMID: 12222584 Review. - Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
Scott SD. Scott SD. Pharmacotherapy. 2002 Sep;22(9 Pt 2):160S-165S. doi: 10.1592/phco.22.14.160s.33398. Pharmacotherapy. 2002. PMID: 12222586 Review.
Cited by
- Ethnic minority disparities in progression and mortality of pre-dialysis chronic kidney disease: a systematic scoping review.
Hounkpatin HO, Fraser SDS, Honney R, Dreyer G, Brettle A, Roderick PJ. Hounkpatin HO, et al. BMC Nephrol. 2020 Jun 9;21(1):217. doi: 10.1186/s12882-020-01852-3. BMC Nephrol. 2020. PMID: 32517714 Free PMC article. - CMV seropositivity determines epoetin dose and hemoglobin levels in patients with CKD.
Betjes MG, Weimar W, Litjens NH. Betjes MG, et al. J Am Soc Nephrol. 2009 Dec;20(12):2661-6. doi: 10.1681/ASN.2009040400. Epub 2009 Oct 9. J Am Soc Nephrol. 2009. PMID: 19820127 Free PMC article. - Possible effects of the new Medicare reimbursement policy on African Americans with ESRD.
Ishani A, Guo H, Arneson TJ, Gilbertson DT, Mau LW, Li S, Dunning S, Collins AJ. Ishani A, et al. J Am Soc Nephrol. 2009 Jul;20(7):1607-13. doi: 10.1681/ASN.2008080853. Epub 2009 Apr 23. J Am Soc Nephrol. 2009. PMID: 19389846 Free PMC article. No abstract available. - Ethnicity, socioeconomic status, and attainment of clinical practice guideline standards in dialysis patients in the United kingdom.
Udayaraj UP, Ben-Shlomo Y, Roderick P, Steenkamp R, Ansell D, Tomson CR, Caskey FJ. Udayaraj UP, et al. Clin J Am Soc Nephrol. 2009 May;4(5):979-87. doi: 10.2215/CJN.06311208. Epub 2009 Apr 8. Clin J Am Soc Nephrol. 2009. PMID: 19357243 Free PMC article. - Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP. Polite BN, et al. J Clin Oncol. 2008 Jun 1;26(16):2659-65. doi: 10.1200/JCO.2007.13.9782. J Clin Oncol. 2008. PMID: 18509177 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical